<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915886</url>
  </required_header>
  <id_info>
    <org_study_id>CR108603</org_study_id>
    <secondary_id>64530440HEP1001</secondary_id>
    <nct_id>NCT03915886</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-64530440 in Healthy Japanese Male Participants</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64530440 in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of
      JNJ-64530440 (JNJ-0440) in healthy Japanese adult male participants after single oral dose
      administration with ascending dose design.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped due to a strategic decision.
  </why_stopped>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">July 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Approximately up to 37 days</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical agent under study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Analyte Concentration (Cmax) of JNJ-0440</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>Cmax is defined as the maximum observed plasma analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Actual Sampling Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax) of JNJ-0440</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>Tmax is defined as actual sampling time to reach maximum observed plasma analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to 24 Hours Postdose (AUC [0- 24h]) of JNJ-0440</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>AUC(0-24h) is area under the plasma concentration-time curve from time zero to 24 hours, calculated by linear-linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to Last Quantifiable Concentration Time (AUC [0- Last]) of JNJ-0440</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>AUC(0-Last) is area under the plasma concentration-time curve from time zero to time of the last measurable (non-below quantification limit) concentration, calculated by linear-linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-0440</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (last) and C(last)/lambda(z); where C(last) is the last observed measurable (non-below quantification limit) concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (Lambda[z]) of JNJ-0440</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-Life (t1/2) of JNJ-0440</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>The t1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic analyte concentration time curve, and is calculated as 0.693/lambda(z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vdz/F)</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>The Vdz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution based on the terminal phase after extravascular administration, uncorrected for absolute bioavailability and calculated as dose/(lambda (z)*AUC[0-infinity]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Clearance (CL/F)</measure>
    <time_frame>Up to follow-up visit (approximately up to Day 9)</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent total clearance of drug after extravascular administration, uncorrected for absolute bioavailability, calculated as dose/AUC(0-infinity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of JNJ-0440 Excreted in Urine within the Time Interval x to y (Ae[x-y])</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <description>Ae(x-y) is the amount of JNJ-0440 excreted into urine for the collection interval from x to y hours, where x and y are the start and end times of the interval, respectively, calculated by multiplying the urinary volume with the urinary concentration for that interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Urinary Recovery (Ae[0-x])</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <description>Ae(0-x) is the sum of Ae values for all collection intervals up to 72 hours postdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cumulative Urinary Recovery (Ae[total])</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <description>Ae(total) is the sum of Ae values for all collection intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of JNJ-0440 Excreted in Urine (Ae%dose[0-x])</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <description>The Ae%dose(0-x) is the percentage of cumulative JNJ-0440 dose recovered into the urine for all collection intervals up to x hours postdose, calculated as (Ae/dose[0-x])∗100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of JNJ-0440 Excreted in Urine (Ae%dose[total])</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <description>Ae%dose(total) is the percentage of total JNJ-0440 dose recovered into the urine for all collection intervals, calculated as (Ae/dose[total])∗100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of JNJ-0440</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <description>The CLr is the renal clearance of the drug, calculated as Ae(total)/AUC(0-infinity).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>JNJ-0440 (Low Dose) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose (low) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-0440 (Medium Dose) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose (medium) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-0440 (High Dose) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose (high) of JNJ-0440 or matching placebo under fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-0440</intervention_name>
    <description>JNJ-0440 tablets will be administered orally.</description>
    <arm_group_label>JNJ-0440 (High Dose) or Placebo</arm_group_label>
    <arm_group_label>JNJ-0440 (Low Dose) or Placebo</arm_group_label>
    <arm_group_label>JNJ-0440 (Medium Dose) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets will be administered orally.</description>
    <arm_group_label>JNJ-0440 (High Dose) or Placebo</arm_group_label>
    <arm_group_label>JNJ-0440 (Low Dose) or Placebo</arm_group_label>
    <arm_group_label>JNJ-0440 (Medium Dose) or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI; weight [kg]/height^2 [m]^2) between 18.0 and 30.0 kilogram per
             meter square (kg/m^2) (inclusive), and body weight not less than 50 kilogram (kg), at
             time of screening

          -  Healthy on the basis of physical examination, medical history, vital signs, and 12
             lead electrocardiogram (ECG) performed at screening. If there are abnormalities, the
             participant may be included only if the investigator judges the abnormalities to be
             not clinically significant or to be appropriate and reasonable for the population
             under study. This determination must be recorded in the participant's source documents
             and initialed by the investigator

          -  Healthy on the basis of clinical laboratory tests performed at screening and at
             admission to the study site. If the results of the biochemistry panel including liver
             enzymes, other specific tests, blood coagulation, hematology, or urinalysis are
             outside the normal reference ranges, the participant may be included only if these are
             grade 1 abnormal values and the investigator judges the abnormalities or deviations
             from normal to be not clinically significant or to be appropriate and reasonable for
             the population under study. This determination must be recorded in the participant's
             source documents and initialed by the investigator

          -  Blood pressure (after the participants has been supine for 5 minutes) between 90 and
             140 millimeter of Mercury (mm Hg) systolic, inclusive, and no higher than 90 mm Hg
             diastolic. If blood pressure is out of range, up to 2 repeated assessments are
             permitted

          -  Must agree not to donate sperm for the purpose of reproduction during the study and
             for a minimum 90 days after receiving the study drug

        Exclusion Criteria:

          -  Any history of confirmed clinically significant skin disease such as, but not limited
             to, dermatitis, eczema, drug rash, psoriasis, food allergy, and urticaria

          -  Clinically significant abnormal physical examination, vital signs, or 12 lead ECG at
             screening or at admission to the study site as deemed appropriate by the investigator

          -  History of confirmed clinically significant drug allergy such as, but not limited to,
             sulfonamides and penicillins, or drug allergy witnessed in previous studies with
             experimental drugs

          -  Known allergy to heparin or history of heparin induced thrombocytopenia

          -  History of drug or alcohol abuse according to Diagnostic and Statistical Manual of
             Mental Disorders (5th edition) (DSM-V) criteria within 5 years before screening or
             positive test result(s) for alcohol and/or drugs of abuse (such as hallucinogens,
             barbiturates, opiates, opioids, cocaine, cannabinoids, amphetamines, and
             benzodiazepines) at screening or at admission to the study site
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sumida Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

